Baseline characteristics across the studies included in the MAIC
| Characteristic . | MANIFEST arm 3 (n = 84) . | COMFORT-I ruxolitinib (n = 155) . | COMFORT-II ruxolitinib (n = 146) . | SIMPLIFY-1 ruxolitinib (n = 217) . | SIMPLIFY-1 momelotinib (n = 215) . | JAKARTA fedratinib 400 mg (n = 96) . | JAKARTA fedratinib 500 mg (n = 97) . |
|---|---|---|---|---|---|---|---|
| Sex, n (%) | |||||||
| Male | 59 (70) | 79 (51) | 83 (57) | 120 (55) | 124 (58) | 54 (56) | 61 (63) |
| Female | 25 (30) | 76 (49) | 63 (43) | 97 (45) | 91 (42) | 42 (44) | 36 (37) |
| MF type, n (%) | |||||||
| Primary | 46 (55) | 70 (45) | 77 (53) | 116 (54) | 128 (60) | 62 (65) | 63 (65) |
| Post-PV | 9 (11) | 50 (32) | 48 (33) | 50 (23) | 48 (22) | 24 (25) | 25 (26) |
| Post-ET | 26 (31) | 35 (23) | 20 (14) | 51 (24) | 39 (18) | 10 (10) | 9 (9) |
| Missing | 3 (4) | — | — | — | — | — | — |
| IPSS status, n (%) | |||||||
| High | 45 (53) | 90 (58) | 88 (60) | 107 (49) | 93 (43) | 39 (41) | 50 (52) |
| Intermediate-1 | 11 (13) | 0 | 0 | 43 (20) | 46 (21) | 0 | 0 |
| Intermediate-2 | 28 (33) | 64 (41) | 58 (40) | 67 (31) | 76 (35) | 57 (59) | 47 (48) |
| Previous hydroxyurea use | NA | NA | |||||
| Yes | 31 (37) | 104 (67) | 110 (75) | 69 (72) | 59 (61) | ||
| No | 53 (63) | 51 (33) | 37 (25) | 27 (28) | 38 (39) | ||
| Platelet count | Median = 293 × 109/L (range, 100-1849) | Median = 262 × 109/L (range, 81-984) | Median = 244 × 109/L | Mean = 302 × 103/μL (SD = 256) | Mean = 301 × 103/μL (SD = 207) | Median = 221 × 109/L (range, 31-1155) | Median = 241 × 109/L (range, 23-873) |
| Hemoglobin | Median, 9 g/dL (range, 7-17) | Mean, 10.5 g/dL (range, 7-17) | <10 g/dL, 45% | Mean, 10.7 g/dL | Mean, 10.6 g/dL | Median, 10.7 g/dL (range, 5-17) | Median, 9.8 g/dL (range, 5-17) |
| Spleen volume, cm3 | |||||||
| Mean | 1845 (458-4782) | NA | NA | NA | NA | NA | NA |
| Median | 1698 (458-4782) | 2598 (478-7462) | 2408 (451-7766) | NA | NA | 2652 (316-6430) | 2366 (388-8244) |
| Transfusion dependent, n (%) | NA | NA | NA | ||||
| Yes | 52 (24) | 53 (25) | 8 (8) | 5 (5) | |||
| No | 152 (70) | 147 (68) | 88 (92) | 92 (95) | |||
| JAK V617F status, n (%) | |||||||
| Positive | 59 (70) | 113 (73) | 110 (75) | 141 (65) | 125 (58) | 62 (65) | 72 (74) |
| Negative | 25 (30) | 42 (27) | 35 (24) | 53 (24) | 61 (28) | 30 (31) | 20 (21) |
| Unknown | — | — | 1 (1) | 23 (11) | 28 (13) | 4 (4) | 5 (5) |
| Characteristic . | MANIFEST arm 3 (n = 84) . | COMFORT-I ruxolitinib (n = 155) . | COMFORT-II ruxolitinib (n = 146) . | SIMPLIFY-1 ruxolitinib (n = 217) . | SIMPLIFY-1 momelotinib (n = 215) . | JAKARTA fedratinib 400 mg (n = 96) . | JAKARTA fedratinib 500 mg (n = 97) . |
|---|---|---|---|---|---|---|---|
| Sex, n (%) | |||||||
| Male | 59 (70) | 79 (51) | 83 (57) | 120 (55) | 124 (58) | 54 (56) | 61 (63) |
| Female | 25 (30) | 76 (49) | 63 (43) | 97 (45) | 91 (42) | 42 (44) | 36 (37) |
| MF type, n (%) | |||||||
| Primary | 46 (55) | 70 (45) | 77 (53) | 116 (54) | 128 (60) | 62 (65) | 63 (65) |
| Post-PV | 9 (11) | 50 (32) | 48 (33) | 50 (23) | 48 (22) | 24 (25) | 25 (26) |
| Post-ET | 26 (31) | 35 (23) | 20 (14) | 51 (24) | 39 (18) | 10 (10) | 9 (9) |
| Missing | 3 (4) | — | — | — | — | — | — |
| IPSS status, n (%) | |||||||
| High | 45 (53) | 90 (58) | 88 (60) | 107 (49) | 93 (43) | 39 (41) | 50 (52) |
| Intermediate-1 | 11 (13) | 0 | 0 | 43 (20) | 46 (21) | 0 | 0 |
| Intermediate-2 | 28 (33) | 64 (41) | 58 (40) | 67 (31) | 76 (35) | 57 (59) | 47 (48) |
| Previous hydroxyurea use | NA | NA | |||||
| Yes | 31 (37) | 104 (67) | 110 (75) | 69 (72) | 59 (61) | ||
| No | 53 (63) | 51 (33) | 37 (25) | 27 (28) | 38 (39) | ||
| Platelet count | Median = 293 × 109/L (range, 100-1849) | Median = 262 × 109/L (range, 81-984) | Median = 244 × 109/L | Mean = 302 × 103/μL (SD = 256) | Mean = 301 × 103/μL (SD = 207) | Median = 221 × 109/L (range, 31-1155) | Median = 241 × 109/L (range, 23-873) |
| Hemoglobin | Median, 9 g/dL (range, 7-17) | Mean, 10.5 g/dL (range, 7-17) | <10 g/dL, 45% | Mean, 10.7 g/dL | Mean, 10.6 g/dL | Median, 10.7 g/dL (range, 5-17) | Median, 9.8 g/dL (range, 5-17) |
| Spleen volume, cm3 | |||||||
| Mean | 1845 (458-4782) | NA | NA | NA | NA | NA | NA |
| Median | 1698 (458-4782) | 2598 (478-7462) | 2408 (451-7766) | NA | NA | 2652 (316-6430) | 2366 (388-8244) |
| Transfusion dependent, n (%) | NA | NA | NA | ||||
| Yes | 52 (24) | 53 (25) | 8 (8) | 5 (5) | |||
| No | 152 (70) | 147 (68) | 88 (92) | 92 (95) | |||
| JAK V617F status, n (%) | |||||||
| Positive | 59 (70) | 113 (73) | 110 (75) | 141 (65) | 125 (58) | 62 (65) | 72 (74) |
| Negative | 25 (30) | 42 (27) | 35 (24) | 53 (24) | 61 (28) | 30 (31) | 20 (21) |
| Unknown | — | — | 1 (1) | 23 (11) | 28 (13) | 4 (4) | 5 (5) |
NA, not available; SD, standard deviation.